2seventy bio plucks Turnstone Biologics exec Bernstein to be new CMO
2seventy bio has hired oncologist and former Turnstone Biologics exec Steven Berstein, M.D., to be its chief medical officer, effective Monday. Bernstein spent more than...
Tag : Biotech
Improving RNA editing for genetic diseases by recruiting the body’s natural protein
Unlike the much-buzzed-about CRISPR-Cas9 gene-editing system, RNA editing doesn’t cause permanent changes to the genome, and could therefore have its own applications in treating genetic...
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Roivant Sciences has spawned another Vant. The latest addition to the clan is Hemavant, a biotech that starts life with a former Eisai drug and...
FDA fingers tox assessment as cause of Denali clinical hold, leaving biotech with a to-do list to regain momentum
Denali Therapeutics now knows what it needs to do to get its Alzheimer’s disease drug DNL919 back on track. Almost one month after the FDA...
Roche, Lilly push back against CMS painting their Alzheimer’s meds with the same brush as Biogen’s Aduhelm
In a rare moment of solidarity among fierce competitors, Biogen’s peers Roche and Eli Lilly are rallying behind the company’s troubled Alzheimer’s disease therapy, Aduhelm,...
ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial
ProQR’s treatment for a congenital eye disease in children failed to improve vision and mobility, a tough pill to swallow that Wall Street spat back...
Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer’s drug trials
Cassava Sciences has chalked up one win in an ongoing battle over the integrity of its clinical trials for Alzheimer’s disease. The FDA is declining...
Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disaster
The 2021 NASH disaster at Metacrine has extended into 2022. The company has fired half its staff and ended work on a preclinical asset intended...
Hunting for cutting-edge biotech, Fujifilm sets up early-stage VC fund
Fujifilm is pushing deeper into early-stage biotech venture capital, providing fresh funding for a new VC unit and rolling its existing investments in areas such...
With approval in sight, ObsEva sells regional rights to women’s health drug for tiny upfront
ObsEva has found a taker for its near-approval uterine fibroid treatment linzagolix. With the oral GnRH antagonist on the cusp of approval on both sides...